Singapore markets open in 39 minutes

Nautilus Biotechnology, Inc. (NAUT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.7800+0.2400 (+9.45%)
At close: 04:00PM EDT
2.7800 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.5400
Open2.5900
Bid2.5700 x 200
Ask3.3200 x 200
Day's range2.5300 - 2.9000
52-week range2.1600 - 4.6500
Volume106,943
Avg. volume80,293
Market cap347.772M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Nautilus Biotechnology Reports First Quarter 2024 Financial Results

    SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. “We continued to make solid progress against our core development goals in Q1,” said Sujal Patel, CEO of Nautilus. “We remain incredibly focused on increasing the scale, stability, and reproducibility of our consumables, assay, instrument, and software

  • GlobeNewswire

    Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024

    SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of th

  • GlobeNewswire

    Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results

    SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. “2023 was a year of significant accomplishment and foundational progress for Nautilus; progress that will continue to build our momentum as we move through 2024 and into the planned launch of our proteome analysis platform”, said Suj